Deadline: 23-Jul-25
Pfizer is requesting proposals for the Independent Medical Education Grant Program for the Clinical Updates and Strategies in the Treatment and Management of First-line mutant Metastatic Colorectal Cancer (mCRC) and Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Area of Interest
- General Area of Interest for this RFP:
- Projects that will be considered for Pfizer support will focus on increasing healthcare professional’s understanding and competence in one or more of the following areas:
- Increase understanding and awareness of the latest clinical data updates and guidelines recommendations relevant to the first line treatment of patients BRAF V600E-mutuant mCRC and mNSCLC.
- Optimize BRAF inhibitor-based treatment for BRAF V600E-mutant mCRC and mNSCLC through proper management of adverse events through dose modifications and supportive care.
- Increase awareness of BRAF V600E biomarker testing and first-line treatment options in mCRC and mNSCLC in the community setting.
- Maximize therapy management strategies of BRAF inhibitor combination therapies through collaboration between experts in academic centers and community oncologists.
- Examples of educational formats that will be considered under this RFP include but are not limited to:
- Creative educational initiatives with the potential for wide-reaching engagement
- Education using online platforms with downloadable resources and reference tools for HCPs and/or patients.
- Professional medical society programs with wide reach to community oncologists caring for patients being treated for BRAF V600E-mutant mCRC and mNSCLC in the first line setting.
- Interactive learnings, case-based learnings, workshops, tumor boards
- Online articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, animations
- It is not the intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
- Projects that will be considered for Pfizer support will focus on increasing healthcare professional’s understanding and competence in one or more of the following areas:
Funding Information
- Expected Approximate Monetary Range of Grant Applications:
- Individual projects requesting up to $250,000 USD will be considered. The estimated total available budget related to this RFP is $500,000 USD.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
Target Audience
- Oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists and other healthcare professionals involved in the care and treatment of patients with mCRC and/or mNSCLC in the community setting.
Eligibility Criteria
- Geographic Scope/Location of Project: United States only
- Applicant Eligibility Criteria
- Applicant organizations to this RFP must be based in United States
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to patient and/or healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role, and the requesting organization must have a key role in the project.
For more information, visit Pfizer.
